Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.47 |
| ▸ | SYK | P43405 | 4/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3726326 | 0.90 | CHEK1 (0.48) | CHEK1ACHEMAP3K11ALKIL2 | |
| SCHEMBL676884 | 0.85 | SYK (0.42) | CHEK1SYKKDRMAP3K11ALK | |
| SCHEMBL676471 | 0.83 | ALK (0.45) | CHEK1SYKKDRALKMAPT | |
| SCHEMBL675791 | 0.81 | CHEK1 (0.55) | CHEK1ACHEMAP3K11ALKIL2 | |
| SCHEMBL676491 | 0.81 | CHEK1 (0.58) | CHEK1ACHE | |
| SCHEMBL13464041 | 0.80 | CHEK1 (0.54) | CHEK1ACHEMAP3K11ALKIL2 | |
| SCHEMBL677985 | 0.78 | CHEK1 (0.49) | CHEK1ACHEMAP3K11ALKMAPT | |
| SCHEMBL676783 | 0.78 | CHEK1 (0.49) | CHEK1ACHEMAP3K11ALKMAPT | |
| SCHEMBL676451 | 0.77 | CHEK1 (0.45) | CHEK1ACHEMAP3K11ALKIL2 | |
| SCHEMBL676885 | 0.77 | CHEK1 (0.41) | CHEK1SYKKDRMAP3K11ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | CHEK1 1744/4885SYK 42/4885KDR 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.